EUVIMEDEUVIMED entdecken
Crossref

DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic Fabry disease

Eleonora Riccio iD, Alessandra Cuomo, Ivana Capuano iD, Letizia Spinelli, Guido Iaccarino, Oriana De Marco iD, Antonio Pisani

Nephrology Dialysis Transplantation · 20.05.2026

DOI: 10.1093/ndt/gfag115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 20.05.2026. Verfasst von Eleonora Riccio und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Chair of Nephrology, Federico II University, Naples, Italy. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Residual proteinuria remains a major determinant of renal disease progression in Fabry disease (FD) despite optimized enzyme replacement or chaperone therapy and maximal renin–angiotensin system (RAS) blockade. Dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonists exert anti-inflammatory, natriuretic, and antifibrotic effects beyond metabolic control. We evaluated the impact of add-on tirzepatide on residual proteinuria in overweight, non-diabetic Fabry patients receiving optimized background therapy.

Methods

In this prospective, proof-of-concept observational study, 15 FD patients with persistent proteinuria ≥0.5 g/24 h despite stable disease-specific therapy and maximal tolerated RAS blockade were treated with tirzepatide for 6 months. The primary endpoint was change in 24-h proteinuria. Secondary endpoints included change in estimated glomerular filtration rate (eGFR), body mass index (BMI), cardiac biomarkers (NT-proBNP, high-sensitivity troponin T), and safety.

Results

Tirzepatide is associated with a progressive reduction in proteinuria, which became statistically significant at Month 1 and continued through Month 6 (1.11 ± 0.23 g/24 h at baseline to 0.35 ± 0.19 g/24 h at 6 months; 68.9% reduction; P < .001). Two-thirds of patients (66.7%) achieved proteinuria <0.5 g/24 h. eGFR remained stable throughout the treatment period (P = .87). Tirzepatide induced significant weight loss, with BMI decreasing from 29.0 (27.1–29.3) kg/m² at baseline to 24.2 (23.4–25.1) kg/m² at Month 6 (P < .001). Beyond the renal effects, cardiac biomarkers also showed significant reductions, with NT-proBNP and high-sensitivity troponin T decreasing by 33.3% (P < .01) and 14.3% (P < .05), respectively, in the absence of structural echocardiographic changes, that may reflect early modulation of myocardial stress. The drug was well tolerated, with mild gastrointestinal symptoms during initial dose titration and no treatment discontinuations.

Conclusions

Add-on dual GIP/GLP-1 receptor agonism is associated with a reduction in residual proteinuria and showed improvements in cardiac biomarkers in overweight Fabry patients receiving optimized therapy, without affecting eGFR. These findings support a multi-pathway nephroprotective strategy beyond substrate reduction and RAS inhibition.

Schlagwörter

Stichwörter der Autor:innen

Fabry diseaseGIP/GLP-1 RAproteinuria

Autor:innen und Institutionen

  • Department of Public Health, Chair of Nephrology, Federico II University, Naples, Italy.
  • Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
  • Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

ORCID-Profile: Eleonora Riccio, Ivana Capuano, Oriana De Marco

Zitieren

APA

Riccio, E., Cuomo, A., Capuano, I., Spinelli, L., Iaccarino, G., De Marco, O., & Pisani, A. (2026). DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic Fabry disease. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag115

Vancouver

Riccio E, Cuomo A, Capuano I, Spinelli L, Iaccarino G, De Marco O, et al. DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic Fabry disease. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag115

BibTeX
@article{Riccio2026,
  author = {Riccio, Eleonora and Cuomo, Alessandra and Capuano, Ivana and Spinelli, Letizia and Iaccarino, Guido and De Marco, Oriana and Pisani, Antonio},
  title = {DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic Fabry disease},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag115}
}
Kostenlos starten →